PT  - JOURNAL ARTICLE
AU  - Gallagher, Molly E.
AU  - Sieben, Andrew J.
AU  - Nelson, Kristin N.
AU  - Kraay, Alicia N. M.
AU  - Lopman, Ben
AU  - Handel, Andreas
AU  - Koelle, Katia
TI  - Considering indirect benefits is critical when evaluating SARS-CoV-2 vaccine candidates
AID  - 10.1101/2020.08.07.20170456
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.07.20170456
4099  - http://medrxiv.org/content/early/2020/08/11/2020.08.07.20170456.short
4100  - http://medrxiv.org/content/early/2020/08/11/2020.08.07.20170456.full
AB  - Significant progress has already been made in development and testing of SARS-CoV-2 vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also known to bring about indirect benefits to a population through the reduction of virus circulation. The indirect effects of SARS-CoV-2 vaccination can play a key role in reducing case counts and COVID-19 deaths. To illustrate this point, we show through simulation that a vaccine with strong indirect effects has the potential to reduce SARS-CoV-2 circulation and COVID-19 deaths to a greater extent than an alternative vaccine with stronger direct effects but weaker indirect effects. Protection via indirect effects may be of particular importance in the context of this virus, because elderly individuals are at an elevated risk of death but are also less likely to be directly protected by vaccination due to immune senescence. We therefore encourage ongoing data collection and model development aimed at evaluating the indirect effects of forthcoming SARS-CoV-2 vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research reported in this paper was supported by NIH/NIGMS grant 3R01GM124280-03S1, NSF grant 2032084, and NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) grant HHSN272201400004C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code to reproduce the results is hosted in a github repository which will be made public upon acceptance of the manuscript.